KeyCorp began coverage on shares of Becton Dickinson and (NYSE:BDX) in a research note released on Friday morning, MarketBeat reports. The brokerage issued an overweight rating and a $260.00 price target on the medical instruments supplier’s stock.

Other equities research analysts also recently issued reports about the company. Zacks Investment Research raised Becton Dickinson and from a hold rating to a buy rating and set a $234.00 price target for the company in a research note on Tuesday, October 31st. Piper Jaffray Companies reaffirmed a buy rating and set a $213.00 price target on shares of Becton Dickinson and in a research note on Tuesday, September 12th. Wells Fargo & Co assumed coverage on Becton Dickinson and in a research note on Friday, September 22nd. They set an outperform rating and a $225.00 price target for the company. Evercore ISI assumed coverage on Becton Dickinson and in a research note on Wednesday, January 3rd. They set an outperform rating and a $245.00 price target for the company. Finally, Argus raised their price target on Becton Dickinson and to $235.00 and gave the stock a buy rating in a research note on Thursday, December 14th. They noted that the move was a valuation call. Five investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Becton Dickinson and currently has an average rating of Buy and an average target price of $230.20.

Shares of Becton Dickinson and (NYSE BDX) opened at $221.40 on Friday. Becton Dickinson and has a one year low of $168.03 and a one year high of $229.68. The company has a debt-to-equity ratio of 1.44, a quick ratio of 5.03 and a current ratio of 5.58. The firm has a market capitalization of $50,790.00, a PE ratio of 47.61, a PEG ratio of 1.70 and a beta of 1.07.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.37 by $0.03. Becton Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The company had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.14 billion. During the same period last year, the business earned $2.12 EPS. The business’s quarterly revenue was down 2.0% on a year-over-year basis. equities research analysts anticipate that Becton Dickinson and will post 10.89 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 29th. Stockholders of record on Friday, December 8th were issued a dividend of $0.75 per share. This is a positive change from Becton Dickinson and’s previous quarterly dividend of $0.73. The ex-dividend date of this dividend was Thursday, December 7th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.36%. Becton Dickinson and’s dividend payout ratio is currently 64.52%.

Several hedge funds and other institutional investors have recently modified their holdings of BDX. Koch Industries Inc. grew its holdings in Becton Dickinson and by 45,268.7% in the 2nd quarter. Koch Industries Inc. now owns 1,398,264 shares of the medical instruments supplier’s stock valued at $1,391,000 after buying an additional 1,395,182 shares during the last quarter. Vanguard Group Inc. grew its holdings in Becton Dickinson and by 8.5% in the 2nd quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock valued at $3,366,809,000 after buying an additional 1,353,780 shares during the last quarter. Winslow Capital Management LLC acquired a new stake in Becton Dickinson and in the 2nd quarter valued at approximately $225,164,000. Janus Henderson Group PLC grew its holdings in Becton Dickinson and by 1,265.9% in the 2nd quarter. Janus Henderson Group PLC now owns 1,210,837 shares of the medical instruments supplier’s stock valued at $236,245,000 after buying an additional 1,122,191 shares during the last quarter. Finally, Parametric Portfolio Associates LLC grew its holdings in Becton Dickinson and by 216.2% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 1,320,259 shares of the medical instruments supplier’s stock valued at $257,596,000 after buying an additional 902,761 shares during the last quarter. 75.53% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/keycorp-begins-coverage-on-becton-dickinson-and-bdx/1799499.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Analyst Recommendations for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with Analyst Ratings Network's FREE daily email newsletter.